Literature DB >> 15331711

Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Javier Fernandez1, Deborah Taylor, Duncan R Morhardt, Kathleen Mihalik, Montserrat Puig, Charles M Rice, Stephen M Feinstone, Marian E Major.   

Abstract

Two chimpanzees, 1535 and 1536, became persistently infected following inoculation with RNA transcripts from cDNA clones of hepatitis C virus (HCV). Analysis of the HCV genomes from both animals showed an accumulation of amino acid substitutions over time. The appearance of substitutions in the envelope genes was associated with increased antienvelope antibody titers. However, extensive mutations were not incorporated into hypervariable region 1 (HVR1). A comparison of the nonsynonymous substitution rate/synonymous substitution rate was made at various time points to analyze selective pressure. The highest level of selective pressure occurred during the acute phase and decreased as the infection continued. The nonsynonymous substitution rate was initially higher than the synonymous substitution rate but decreased over time from 3.3 x 10(-3) (chimpanzee 1535) and 3.2 x 10(-3) (chimpanzee 1536) substitutions/site/year at week 26 to 1.4 x 10(-3) (chimpanzee 1535) and 1.7 x 10(-3) (chimpanzee 1536) at week 216, while the synonymous substitution rate remained steady at approximately 1 x 10(-3) substitutions/site/year. Analysis of PCR products using single-stranded conformational polymorphism indicated a low level of heterogeneity in the viral genome. The results of these studies confirm that the persistence of infection is not solely due to changes in HVR1 or heterogeneity and that the majority of variants observed in natural infections could not arise simply through mutation during the time period most humans and chimpanzees are observed. These data also indicate that immune pressure and selection continue throughout the chronic phase. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331711      PMCID: PMC514970          DOI: 10.1128/JVI.78.18.9782-9789.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.

Authors:  A A Kolykhalov; E V Agapov; K J Blight; K Mihalik; S M Feinstone; C M Rice
Journal:  Science       Date:  1997-07-25       Impact factor: 47.728

2.  The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.

Authors:  S Okada; Y Akahane; H Suzuki; H Okamoto; S Mishiro
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

Review 3.  Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.

Authors:  J Bukh; R H Miller; R H Purcell
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

4.  A proposed system for the nomenclature of hepatitis C viral genotypes.

Authors:  P Simmonds; A Alberti; H J Alter; F Bonino; D W Bradley; C Brechot; J T Brouwer; S W Chan; K Chayama; D S Chen
Journal:  Hepatology       Date:  1994-05       Impact factor: 17.425

5.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope.

Authors:  T Kaneko; T Moriyama; K Udaka; K Hiroishi; H Kita; H Okamoto; H Yagita; K Okumura; M Imawari
Journal:  Eur J Immunol       Date:  1997-07       Impact factor: 5.532

7.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.

Authors:  L J van Doorn; I Capriles; G Maertens; R DeLeys; K Murray; T Kos; H Schellekens; W Quint
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

10.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

View more
  23 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 2.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

3.  Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.

Authors:  Jens Bukh; Philip Meuleman; Raymond Tellier; Ronald E Engle; Stephen M Feinstone; Gerald Eder; William C Satterfield; Sugantha Govindarajan; Krzysztof Krawczynski; Roger H Miller; Geert Leroux-Roels; Robert H Purcell
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

4.  Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.

Authors:  Jannick Prentoe; Tanja B Jensen; Philip Meuleman; Stéphanie B N Serre; Troels K H Scheel; Geert Leroux-Roels; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

5.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 6.  T cell responses in hepatitis C virus infection: historical overview and goals for future research.

Authors:  Lauren Holz; Barbara Rehermann
Journal:  Antiviral Res       Date:  2014-11-26       Impact factor: 5.970

7.  Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins.

Authors:  Shingo Takikawa; Ronald E Engle; Kristina N Faulk; Suzanne U Emerson; Robert H Purcell; Jens Bukh
Journal:  J Gen Virol       Date:  2009-11-11       Impact factor: 3.891

8.  Apparently nonspecific enzyme elevations after portal vein delivery of recombinant adeno-associated virus serotype 2 vector in hepatitis C virus-infected chimpanzees.

Authors:  Terence R Flotte; Jason Goetzmann; James Caridi; Joseph Paolillo; Thomas J Conlon; Mark Potter; Christian Mueller; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

9.  Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee.

Authors:  MinKyung Yi; Fengyu Hu; Michael Joyce; Vikas Saxena; Christoph Welsch; Deborah Chavez; Bernadette Guerra; Daisuke Yamane; Ronald Veselenak; Rick Pyles; Christopher M Walker; Lorne Tyrrell; Nigel Bourne; Robert E Lanford; Stanley M Lemon
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

Review 10.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.